Full-Time

Scientist II

Polysaccharide Analytical Development

Confirmed live in the last 24 hours

Vaxcyte

Vaxcyte

201-500 employees

Develops vaccines for bacterial infections

Biotechnology
Healthcare

Compensation Overview

$128k - $143kAnnually

+ Equity Component

Mid

San Carlos, CA, USA

Position is onsite in San Carlos, CA.

Category
Lab & Research
Life Sciences
Required Skills
Data Analysis
Requirements
  • PhD in Chemistry, Analytical Chemistry, Biochemistry, or related field with 3+ years relevant industry experience; MS with 8+years of industry experience or BS with 12+ years of industry experience in Pharma/ Biotech industry required.
  • Must have recent experience in Assay automation with automated and high throughput instruments such as Tecan liquid handlers.
  • Experience in chemical/biological/immunological assays such as plate based spectrometric methodology, and ELISA/MSD.
  • Ideal candidate will have a background in analytical chemistry principles and hands-on experience with modern analytical instrumentations commonly used in the analysis and characterization of drug candidates.
  • Experience in carbohydrate analysis is a plus, for example in HPAEC-PAD, colorimetric methods, HPLC, SEC-MALS, and LC-MS.
  • Familiarity with Analytical method development/qualification concepts.
  • Attention to detail and excellent skills in record keeping/ documentation.
  • Critical thinking and ability to analyze data.
  • Strong interpersonal skills; ability to communicate effectively both verbally and in written formats.
  • Ability to work under supervision in a fast-paced, cross-functional environment and collaborate effectively with other team members. Eagerness and ability to learn and understand new concepts with ease.
Responsibilities
  • Independently design, execute, and interpret routine in-house assays to analyze and characterize polysaccharide intermediates and in-process samples.
  • Responsible for the overall quality and compliance of all the testing.
  • Responsible for routine instrument maintenance (HPLC, SEC-MAL, GCMS, HPEAC-PAD) and troubleshooting.
  • Troubleshoot various issues during analytical method development.
  • Complete any assigned tasks and report data in high quality and promptly.
  • Provide technical direction, mentorship, and coaching to junior scientists.
  • Keep accurate and detailed records of experiments in laboratory notebooks and Benchling entries.
  • Summarize data and communicate to cross-functional teams timely and clearly.
  • Work within a team environment and provide support to further team objectives.
  • Support daily lab operations.

Vaxcyte develops vaccines aimed at preventing bacterial infections, focusing on diseases like invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella. Their lead product, VAX-24, is a pneumococcal conjugate vaccine that targets 24 strains of the Streptococcus pneumoniae bacteria and has received Breakthrough Therapy designation from the FDA. Vaxcyte utilizes advanced chemistry and a proprietary cell-free protein synthesis platform, XpressCF™, to create vaccines that can effectively address the complex defenses of bacteria while eliciting a strong immune response. This method sets them apart from traditional cell-based vaccine production. The company's goal is to develop broad-spectrum vaccines that can significantly reduce the impact of bacterial diseases on global health.

Company Stage

IPO

Total Funding

$273.3M

Headquarters

Foster City, California

Founded

2013

Growth & Insights
Headcount

6 month growth

24%

1 year growth

63%

2 year growth

137%
Simplify Jobs

Simplify's Take

What believers are saying

  • VAX-24 received FDA Breakthrough Therapy designation, expediting its development and review process.
  • The global pneumococcal vaccines market is projected to grow at a CAGR of 5.6% by 2030.
  • Recent funding rounds indicate strong investor confidence in Vaxcyte's innovative vaccine solutions.

What critics are saying

  • Competition from mRNA technology developers like Moderna may impact Vaxcyte's market position.
  • Potential clinical trial delays could affect vaccine approval and commercialization timelines.
  • Dependence on XpressCF™ platform scaling may pose production challenges if inefficiencies arise.

What makes Vaxcyte unique

  • Vaxcyte uses a proprietary cell-free protein synthesis platform, XpressCF™, for vaccine development.
  • Their lead product, VAX-24, targets 24 strains of Streptococcus pneumoniae bacteria.
  • Vaxcyte's vaccines aim to combat bacterial infections like pneumococcal disease and Group A Strep.

Help us improve and share your feedback! Did you find this helpful?